CardioSomaticsCardioSomatics2221-71852658-5707Eco-Vector4503210.26442/CS45032Research ArticleSerpovidno-kletochnaya anemiya: sluchay iz klinicheskoy praktikiShapchenkoAnna Valer'evna-ArabidzeGrigoriy Guramovich-MuslimovaOl'ga Valer'evna-FishchenkoSvetlana Genrikhovna-SkryabinaElena Olegovna-PolyakovaOl'ga Vladimirovna-NeskaromnayaSvetlana Alekseevna-1509201343525824092020Copyright © 2013, Eco-Vector2013серповидно-клеточная анемиягемоглобин Sгетерозиготная формаb-талассемия[Воробьев А.И. Серповидноклеточная анемия. Руководство по гематологии. Под ред. А.И.Воробьева. М.: Медицина, 1985; 2: 86–9.][Окороков А.Н. Гемолитические анемии. В кн.: Диагностика болезней внутренних органов. М.: Медицинская литература, 2006; 4: 112–204.][Серповидноклеточная анемия и другие гемоглобинопатии. ВОЗ. Информационный бюллетень. 2011; с. 308.][Chang J, Patton J.T, Sarkar A et al. GMI-1070, a novel pan - selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010; 116 (10): 1779–86.][Chase S, Thackray H, Magnani J.L, Wun T. Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070. Blood (ASH Annual Meeting Abstracts) 2011; 118 (21): 851.][Charache et al. The effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317–22.][De Franceschi L, Cappellini M.D, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost 2011; 37 (3): 226–36.][Gutsaeva D.R, Parkerson J.B, Yerigenahally S.D et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood 2011; 117 (2): 727–35.][Haas Michael J. Two edges of sickle cell disease. Science–Business eXchange 2011; 4 (3): 3–5.][Hoppe C, Kuypers F, Larkin S et al. A pilot study of the short - term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol 2011; 153 (5): 655–63.][Kutlar A, Ataga K.I, Mc Mahon L et al. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol 2012; 87 (5): 536–9.][Lee S.P, Ataga K.I, Zayed M et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol 2007; 139 (4): 612–20.][Qari M.H, Aljaouni S.K, Alardawi M.S et al. Reduction of painful vaso - occlusive crisis of sickle cell anaemia by tinzaparin in a double - blind randomized trial. Thromb Haemost 2007; 98 (2): 392–6.][Vichinsky E. Emerging ‘A’ therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. ASH Education Book 2012; 1: 271–5.][Wallace K.L, Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 2010; 166: 5010–20.]